Company intelligence / Profile preview

Apnimed, Inc.

Cambridge, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Apnimed's lead candidate AD109 has completed Phase 2b trials with positive results and is currently in two Phase 3 clinical trials (SynAIRgy and LunAIRo) with topline data expected in Q2 and Q3 2025. The company has also begun a Phase 2A trial (RESTEADY) for SASS-001 with topline results expected in 1H 2026.[6][8]

Therapeutic areas: Pulmonology
Modalities: Small moleculesoral drug combinations
Industry: Biotech

Drug pipeline

10 assets

AD109

9 more assets in the full pipeline.

Request access →

Partnerships

Shionogi & Co., Ltd. (joint venture called Shionogi Apnimed Sleep Science or SASS)[6][10]

Beyond the preview

Go deeper on Apnimed, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apnimed, Inc..

Explore the full profile